co.don AG to grow cartilage cell transplants for Asklepios Group
• Framework agreement signed with Germany’s largest private clinic group
Teltow - The biotech company co.don AG is to provide the Asklepios Group with cartilage cell transplants from its laboratories in Teltow from July 2011. The company’s German distribution partner, ORMED GmbH, was able to sign a corresponding framework agreement. This will enable patients at the Asklepios Clinics throughout Germany to be treated with the cell-based biological drug ARTROCELL 3D® / co.don chondrosphere®. The product is to be used for the regenerative treatment of damaged cartilage, in knee joints for instance.
“The Asklepios Clinics are a strong partner for the deployment of our products for the treatment of damaged articular cartilage”, says Dr. Andreas Baltrusch, CEO of co.don AG. “The clinics are the market leader in the private hospital sector and are well-known for having the highest quality standards and practising cutting-edge, patient-oriented medicine. The cell-biological products from co.don AG are an ideal addition to the services offered by the Askepios Clinics”, Baltrusch added.
The product ARTROCELL 3D® / co.don chondrosphere® is manufactured 100 per cent autologously, i.e. from the patient’s own cells using their own serum. No genetic manipulation is applied to breed or grow these cells and no external substances such as antibiotics or antifungal agents are used.
These cartilage cell transplants are used in orthopaedic surgery to treat articular cartilage defects. The transplants from the laboratories of co.don AG are inserted orthopaedically into each defective area. This ensures that the operation is as comfortable for the patient as possible. The use of regenerative cartilage surgery at an early stage can obviate the need for a subsequent prosthesis. As they are made exclusively from the body’s own substances, the cartilage cell transplants used for the treatment are not expected to cause any rejection. The success rate for this regenerative treatment method is over 90 per cent.
About co.don AG:
The company is based in Teltow, Brandenburg, and was founded in 1993. Since 2001 the bio-pharmaceutical specialist has been listed on the Frankfurt Stock Exchange (ISIN: DE0005173603). co.don AG uses tissue engineering – the cultivation and growth of autologous tissue cells – to develop innovative products and therapeutic concepts for the orthopaedic and neurosurgical markets. The cell-based biological drugs (autologous cell transplants for articular cartilage and intervertebral disks) are produced without the use of antibiotics, growth factors and genetic engineering. The Management Board of co.don® AG is made up of Dr Andreas Baltrusch (CEO) and Ms Vilma Siodla (COO). Further information is available from: www.codon.de
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.